Arcturus Therapeutics
ARCT
33 hedge funds and large institutions have $11.5M invested in Arcturus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.23% less ownership
Funds ownership: 8.44% → 5.21% (-3.2%)
21% less funds holding
Funds holding: 42 → 33 (-9)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
40% less call options, than puts
Call options by funds: $39K | Put options by funds: $65K
66% less capital invested
Capital invested by funds: $34.2M → $11.5M (-$22.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$606K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$265K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$247K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$235K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.91M |
| 2 |
VMI
VHCP Management II
New York
|
-$1.79M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.71M |
| 4 |
BC
Broadfin Capital
New York
|
-$1.11M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.05M |
ARCT Hedge Fund Activity: Q1 2017 in Review
33 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2017, worth a combined $11.5M — down 66% from $34.2M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ARCT and 11 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was Morgan Stanley, adding an estimated $606K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.91M sold.
- 33 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2017, down from 42 in Q4 2016.
- Funds reported $11.5M of Arcturus Therapeutics stock for Q1 2017, down 66% quarter-over-quarter.
- 11 funds opened new Arcturus Therapeutics positions in Q1 2017 and 18 closed out, a net change of -7 holders.
- The largest Arcturus Therapeutics buyer in Q1 2017 was Morgan Stanley, an estimated $606K added.
- The largest Arcturus Therapeutics seller in Q1 2017 was Baker Bros. Advisors, an estimated $4.91M sold.
Based on aggregated 13F filings for Q1 2017.